ACT指导肝素化在开放腹主动脉瘤修复术中的随机对照试验
因无效提前终止,共纳入294例患者。结果显示ACT组主要疗效终点(30天血栓栓塞并发症和全因死亡)发生率为22.8%,对照组为25.5%,绝对差异-2.7%(95%CI -12.5至7.1%),未达优效;ACT组出血并发症和死亡发生率更高。
要点
- ACT指导肝素化未减少30天血栓栓塞并发症和全因死亡。
- ACT组出血并发症绝对差异9.2%(95%CI -1.8至20.2%)。
- ACT组死亡绝对差异7.9%(95%CI 2.3至13.6%),高于对照组。
研究设计与样本
- 多中心、随机对照、单盲、优效性试验(NCT04061798),因无效提前终止,共纳入294例择期开放AAA修复患者。
主要发现
- 主要疗效终点(30天血栓栓塞并发症和全因死亡)ACT组34例(22.8%),对照组37例(25.5%),绝对差异-2.7%(95%CI -12.5至7.1%)。
- 出血并发症绝对差异9.2%(95%CI -1.8至20.2%),ACT组更高。
- 死亡绝对差异7.9%(95%CI 2.3至13.6%),ACT组更高。
- 血栓栓塞并发症发生率绝对差异-5.4%(95%CI -15.0至4.2%),无差异。
局限性
- 试验因无效提前终止,样本量有限。
- 单盲设计可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The optimal dosage of intravenous unfractionated heparin and the role of monitoring its effect using activated clotting time (ACT) to prevent thromboembolic complications (TECs) during open abdominal aortic aneurysm (AAA) repair are uncertain. This trial aimed to compare ACT guided heparinisation with a single dose of 5 000 international units (IU) of heparin. METHODS: This was a multicentre, randomised controlled, single blinded, superiority trial (NCT04061798). Patients undergoing elective open AAA repair were randomly assigned (1:1) to receive either ACT guided heparinisation with a dose of 100 IU/kg with a target duration of 200 seconds or a single heparin bolus of 5 000 IU as a control group. The primary efficacy outcome was the combined incidence of TECs and all cause death at 30 days. The safety outcome was the incidence of bleeding complications. ACT measurements were performed using the same device to limit variability. RESULTS: The trial was ended prematurely due to futility after inclusion of 294 patients. After randomisation, 149 patients received ACT guided heparinisation and 145 patients were assigned to the control group. The primary outcome occurred in 34 patients (22.8%) in the ACT group vs. 37 patients (25.5%) in the control group (absolute difference -2.7%, 95% confidence interval [CI] -12.5 - 7.1%). Bleeding complications (absolute difference 9.2%, 95% CI -1.8 - 20.2%) and deaths (absolute difference 7.9%, 95% CI 2.3 - 13.6%) were higher in the ACT group. No difference was found in the incidence of TECs (absolute difference -5.4%, 95% CI -15.0 - 4.2%). CONCLUSION: In patients undergoing open AAA repair, heparinisation with 100 IU/kg and ACT monitoring at a target of 200 seconds did not reduce the primary efficacy outcome and increased the risk of peri-operative bleeding compared with a single bolus of 5 000 IU. Additionally, an increased mortality rate was observed.
引用
- Jongkind V, Steunenberg TAH, Roosendaal LC, et al. Editor's Choice - Activated Clotting Time Guided Heparinisation during Open Abdominal Aortic Aneurysm Repair (ACTION-1): A Randomised, Multicentre, Single Blind, Superiority Trial. Eur J Vasc Endovasc Surg. 2025. PMID: 40684876. doi:10.1016/j.ejvs.2025.07.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。